Trastuzumab biosimilar (Hanwha Biologics)

曲妥珠单抗生物类似药 (Hanwha Biologics)

Report date: 2025/02/13 20:00:05

Base Information

Drug NameTrastuzumab biosimilar (Hanwha Biologics)
Drug Alias Name曲妥珠单抗生物仿制药 (Hanwha Biologics)TuznueHervelousHD-201
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsStomach NeoplasmsBreast Neoplasms
Global Approved IndicationsStomach NeoplasmsBreast Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2024/09/19
Country/TerritoryBulgariaUkrainePoland +[15
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesHanwha Biologics
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsStomach NeoplasmsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeL01XC03
Related LinksN/A